- Source: NITD008
NITD008 is an antiviral drug classified as an adenosine analog (a type of nucleoside analog). It was developed as a potential treatment for flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as dengue virus, West Nile virus, yellow fever virus, Powassan virus, hepatitis C virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Zika virus. However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.
See also
Favipiravir, a drug approved by China, Germany, Indonesia, Iran, Japan, Thailand, and Turkey for treating COVID-19 patients
MK-608, a drug with a similar structure
Remdesivir, FDA approved antiviral drug with a similar structure
Ribavirin, another antiviral drug with teratogenic side effects that was patented by Merck in 1971 and approved by the FDA in 1986